

INVO Fertility to Participate in H.C. Wainwright's 28th Annual Global Investment Conference

Virtual company presentation will be available beginning September 11, 2026, at 7:00 a.m. ET

SARASOTA, Fla., Aug. 28, 2026 (GLOBE NEWSWIRE) — INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, today announced that it will participate in the 28th Annual H.C. Wainwright Global Investment Conference, taking place September 14 through September 16, 2026, at the Lotte New York Palace Hotel in New York City.

A pre-recorded presentation from the Company will be available on demand as a part of the conference beginning Friday, September 11, 2026, at 7:00 a.m. ET. A copy of the slide presentation is available on the investor relations portion of the INVO Fertility website at <https://invofertility.com/investors/events-presentations/>.

Members of INVO Fertility's management team will be available for one-on-one investor meetings during the conference. Investors interested in scheduling a meeting should contact their H.C. Wainwright representative at meetings@hcwco.com, or INVO's investor relations at INVO@lythampartners.com.

Event Details

Conference: 28th Annual H.C. Wainwright Global Investment Conference

Conference Dates: September 14-16, 2026

Pre-Recorded Virtual Presentation: Available beginning Friday, September 11, 2026, at 7:00 a.m. ET

Presentation Access: H.C. Wainwright conference portal

About INVO Fertility

We are a healthcare services fertility company dedicated to expanding access to assisted reproductive technology (“ART”) care to patients in need. Our principal commercial strategy is focused on building, acquiring, and operating fertility clinics and related businesses and technologies. Our acquisition strategy focuses on U.S.-based, profitable fertility clinics. Our clinics offer a variety of fertility services including in vitro fertilization (“IVF”) and the intravaginal culture (“IVC”) procedure enabled by INVOcell. We have four operational fertility clinics in the United States. We also continue to engage in the sale and distribution of INVOcell to third-party owned and operated fertility clinics. INVOcell is a proprietary and revolutionary medical device, and the first to allow fertilization and early embryo development to take place in vivo within the woman's body. For more information, please

visit invo fertility.com.

For more information, please contact:

INVO Fertility, Inc.

Steve Shum, CEO

978-878-9505

sshum@invo fertility.com

Investor Contact

Lytham Partners, LLC

Robert Blum

602-889-9700

INVO@lythampartners.com

